Intuniv Does Not Cause Weight Gain
Intuniv (extended-release guanfacine) is not associated with clinically significant weight gain and actually shows minimal weight changes compared to placebo. According to the FDA label, patients taking Intuniv had a mean increase of only 0.5 kg (1 lb) compared to placebo over comparative treatment periods, and BMI percentiles remained stable at 12 months 1.
Key Evidence on Weight Effects
The FDA-approved prescribing information explicitly states that patients taking Intuniv demonstrated similar growth compared to normative data 1. While patients receiving Intuniv for at least 12 months gained an average of 8 kg (17 lbs) in weight and 8 cm (3 in) in height, these changes represent normal developmental growth patterns, as the height, weight, and BMI percentiles remained stable throughout treatment 1.
Supporting Research Data
A large longitudinal database study of 47,910 patients confirmed these findings, demonstrating that guanfacine monotherapy was not associated with clinically meaningful deviations from normal z-score trajectories for weight 2. This held true whether guanfacine was used as first-line treatment (n=943) or non-first-line treatment (n=796).
A more recent Japanese study of ADHD children receiving guanfacine extended-release found no significant differences in BMI-SD scores before and after approximately 2 years of treatment 3. The frequency of patients with BMI-SD scores >2.0 SD increased only slightly from 7.8% to 13.7%, which was not statistically significant and similar to untreated controls.
Clinical Practice Guidelines Context
The 2019 AAP clinical practice guidelines list the adverse effects of extended-release guanfacine as somnolence, dry mouth, dizziness, irritability, headache, bradycardia, hypotension, and abdominal pain—notably absent from this list is weight gain 4. This contrasts sharply with stimulant medications, which are associated with appetite loss and decreased growth velocity.
Important Clinical Distinction
This makes guanfacine particularly valuable for patients who experience appetite suppression and weight loss on stimulant medications. When guanfacine is used adjunctively with stimulants, any observed weight changes are attributable to the stimulant component rather than guanfacine itself 2.
Bottom Line for Clinical Practice
- Monitor weight and height as standard practice, but reassure families that guanfacine itself does not cause problematic weight gain
- Consider guanfacine as a preferred option when weight concerns exist with stimulant therapy
- The modest 0.5 kg difference from placebo is clinically insignificant and should not influence prescribing decisions
- Normal developmental weight gain will continue on guanfacine, maintaining appropriate growth trajectories